Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessMarkets

Ind-Swift Labs locked in upper circuit on FDA all-clear for Punjab facility

The EIR has been issued without any Form 483 observations, said the company in its BSE filing.

May 12, 2020 / 05:16 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Ind-Swift Laboratories shares were locked in upper circuit on May 12 after the company received EIR from the US health regulator for its Punjab facility.

The stock closed at Rs 21.65, up 4.84 percent on the BSE.

Ind-Swift Laboratories said it had received the Establishment Inspection Report (EIR) from the USFDA for the surveillance good manufacturing practise (GMP) inspection of its API manufacturing facility in Punjab's Dera Bassi.

The USFDA inspection was conducted from March 9 to 13. EIR has been issued without any Form 483 observations, the company told BSE.

The APIs manufactured at the Dera Bassi unit are supplied to more than 70 countries, the company said.

Ind-Swift supplies 15 APIs to its customers based in the US.

Moneycontrol News
first published: May 12, 2020 05:16 pm

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347